Health Condition 1: null- Chronic Bronchitis
Conditions
Interventions
Intervention1: Vyaghri Haritaki: Dose-10 gm twice daily
Dosage form-Avaleha
Route of Administration-Oral
Time of Administration-Twice a day before food
Anupana-Lukewarm Water
Packing form-300 gm
Sponsors
Central Council for Research in Ayurvedic Sciences CCRAS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex aged between 16 to 70 years. 2. Patients with history of uncomplicated Chronic Bronchitis. (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row). 3. Patient willing and able to participate in the study for 16 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients suffering from Acute Bronchitis. 2. Patients having PEFR 3. Presence of other pulmonary diseases like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc. 4. Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%) 5. Patients with poorly controlled Hypertension ( >=160 / 100 mm Hg) 6. Patients on prolonged ( > 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 7. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.) 8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 9. Symptomatic patients with clinical evidence of Heart failure. 10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL). 11. Smokers/alcoholics and/or drug abusers. 12. H/o hypersensitivity to the trial drug or any of its ingredients. 13. Patients who have completed participation in any other clinical trial during the past six (06) months. 14. Pregnant or lactating women. 15. Any other condition which the Principal Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the clinical symptoms of chronic bronchitis viz: Productive cough, Dyspnoea, Wheezing, Chest pain, Sore throat and Nasal congestionTimepoint: Baseline-14th day-28th day-42nd day-56th day-70th day-84th day and at the end of follow up of 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in St. Georgeâ??s Respiratory Questionnaire (SGRQ) scoresTimepoint: Baseline-14th day-28th day-42nd day-56th day-70th day-84th day and at the end of follow up of 2 weeks | — |
Countries
India
Contacts
Public ContactDr Pradeep Dua
Central Council for Research in Ayurvedic Sciences (CCRAS)
Outcome results
None listed